Different inclusion and exclusion criteria, such as whether or not patients with NMOSD had to test positive for the anti-AQP4 antibody, have been employed in studies comparing NMOSD and MS, which may have led to different findings. This evidence concerns the gene AQP4 and myeloid sarcoma.